Sarepta (SRPT) COO has 1,097 shares withheld for RSU tax obligations

Rhea-AI Filing Summary

Sarepta Therapeutics, Inc. Chief Operating Officer Ian Michael Estepan reported a routine tax-related share disposition. On March 11, he had 1,097 shares of common stock withheld by the company at $17.03 per share to cover tax obligations tied to vesting of restricted stock units granted on March 10, 2025. After this withholding, he directly held 201,983 shares of Sarepta common stock, indicating he retains a substantial equity position in the company.

Insights

Insider transactions analyst

Routine tax withholding; no open-market buying or selling.

The filing shows Sarepta Therapeutics COO Ian Michael Estepan had 1,097 common shares withheld at $17.03 per share to satisfy tax obligations on vested restricted stock units granted on March 10, 2025. This is coded as a tax-withholding disposition.

Tax-withholding events are compensation mechanics rather than discretionary trades. No open-market purchases or sales were reported, and Estepan’s direct holdings stand at 201,983 shares after the transaction, suggesting the economic impact relative to his total position is minor.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Estepan Ian Michael

(Last) (First) (Middle)

215 FIRST STREET

SUITE 415

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Sarepta Therapeutics, Inc. [ SRPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/11/2026		F(1)		1,097	D	$17.03	201,983	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares were withheld by the Company to satisfy tax withholding obligations related to vesting of restricted stock units granted on March 10, 2025.

	/s/ Cristin L. Rothfuss, as Attorney-in-Fact for Ian Michael Estepan	03/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Sarepta Therapeutics (SRPT) report for Ian Michael Estepan?

Sarepta Therapeutics reported that COO Ian Michael Estepan had 1,097 common shares withheld on March 11 to cover tax obligations. The shares were withheld at $17.03 per share in connection with vesting of restricted stock units granted on March 10, 2025.

Was the Sarepta Therapeutics (SRPT) Form 4 a market sale by the COO?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. The company withheld 1,097 shares at $17.03 per share to satisfy tax obligations from restricted stock unit vesting, a standard administrative transaction rather than a discretionary sale.

How many Sarepta Therapeutics (SRPT) shares does the COO hold after this Form 4 transaction?

Following the tax-withholding event, COO Ian Michael Estepan directly holds 201,983 shares of Sarepta common stock. This figure reflects his position after 1,097 shares were withheld by the company to cover tax obligations related to vested restricted stock units.

What price per share was used for the Sarepta (SRPT) tax withholding on the COO’s shares?

The tax-withholding disposition used a price of $17.03 per Sarepta common share. At this price, the company withheld 1,097 shares from COO Ian Michael Estepan to satisfy tax obligations triggered by the vesting of restricted stock units granted on March 10, 2025.

What triggered the Sarepta Therapeutics (SRPT) share withholding reported on the Form 4?

The share withholding was triggered by the vesting of restricted stock units granted on March 10, 2025. To satisfy related tax obligations, Sarepta withheld 1,097 common shares from COO Ian Michael Estepan at a value of $17.03 per share instead of him paying cash taxes.

Does the Sarepta (SRPT) Form 4 indicate options or derivative exercises by the COO?

No, the Form 4 does not show any option or derivative exercises. It reports only a tax-withholding disposition of 1,097 common shares, tied to vesting of restricted stock units granted on March 10, 2025, with no remaining derivative positions listed in the filing data provided.